Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOXR0916 + Atezolizumab in Advanced Solid Tumors
NCT02410512Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2015
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of Vonlerolizumab in solid tumor (2 arms), sponsored by Genentech. Primary endpoints: Number of Participants with Dose-Limiting Toxicities at 21 days and Number of Participants with Adverse Events up to 3 years. Started Apr 2015; status: completed.
02
Drugs
Vonlerolizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02410512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410512.